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Abstract: Poor growth, micronutrient deficiencies and episodes of diarrhea and  
respiratory infections occur frequently in HIV-infected children. We investigated whether  
multi-micronutrient supplementation would improve the growth performance and reduce 
the number of episodes of diarrhea and/or of respiratory symptoms in HIV-infected 
children. In a double-blind randomized trial, HIV-infected South African children aged  
4–24 months (n = 201) were assigned to receive multi-micronutrient supplements or 
placebo daily for six months. The children were assessed for respiratory symptoms or 
diarrhea bi-weekly; weights and heights were measured monthly. In total, 121 children 
completed the six month follow up study period (60%). A total of 43 children died; 27 of 
them had received supplements. This difference in mortality was not statistically 
significant (p = 0.12). Weight-for-height Z-scores improved significantly (p < 0.05) among 
children given supplements compared with those given placebo (0.40 (0.09–0.71)) versus 
−0.04 (−0.39–0.31) (mean (95% CI)). Height-for-age Z-scores did not improve in both 
treatment groups. The number of monthly episodes of diarrhea in the placebo group  
(0.36 (0.26–0.46)) was higher (p = 0.09) than in the supplement group (0.25 (0.17–0.33)) 
and the number of monthly episodes of respiratory symptoms was significantly higher  
(p < 0.05) among children on placebos (1.01 (0.83–1.79)) than those on supplements (0.66 
(0.52–0.80)). Multi-micronutrient supplements significantly improved wasting and reduced 
the number of episodes of diarrhea and respiratory symptoms. 
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1. Introduction 
In 2011, there were 330,000 children younger than 15 years worldwide who were newly infected 
with HIV and 90% of them were in Sub-Saharan Africa [1]. Children who are infected with HIV are 
known to be at high risk for poor nutritional status, infections and poor growth performance [2–4]. 
Growth failure in HIV-infected children is associated with an increased risk of mortality [5,6]. 
Episodes of diarrhea and of respiratory symptoms appear to be more common in HIV-infected children 
than in uninfected children [4]. 
Deficiencies of micronutrients, especially of vitamin A and zinc have been associated with diarrhea 
and respiratory diseases [7,8]. Micronutrient status also influences growth. Deficiencies of zinc and of 
iron have been associated with impaired growth [9,10]. Vitamin A and carotenoid status were 
demonstrated to be independent predictors of growth failure in HIV-infected Malawian children [11]. 
Micronutrient deficiencies seem to be common and more severe in HIV-infected children compared 
with uninfected ones [2,12]. 
Studies on the effect of micronutrient supplementation on growth and morbidity in malnourished 
children have not always resulted in undeniably positive outcomes. Vitamin A supplementation has 
been shown to be beneficial in reducing the risk of diarrhea, but may be detrimental against respiratory 
infections [7,13]. Zinc supplementation may improve growth [9] and reduce the incidence of diarrhea 
and respiratory infections in young children [14]. However, another study indicated that zinc 
supplementation increases respiratory infections [15], although adding vitamin A seems to reduce the 
adverse effects of zinc on respiratory infections [16]. Micronutrient deficiencies are seldom limited to 
a single micronutrient, therefore it has been suggested that supplements that contain an array of 
micronutrients should be provided [17]. 
Since HIV-infected children might be severely malnourished, they may profit most from the 
beneficial effects of multi-micronutrient administration. Unfortunately, such studies are scarce. The 
aim of the present study was to test the hypothesis that daily multi-micronutrient supplementation for 
six months would improve the weight-for-height and height-for-age Z-scores by 30% compared to 
placebo in HIV-infected young South African children who are not yet on antiretroviral therapy 
(ART). It was also hypothesized that the six months supplementation would reduce the number of 
episodes of diarrhea or respiratory symptoms by 30% in the same group of children. 
2. Methods 
The study was conducted from the Doctor George Mukhari hospital in Ga-Rankuwa, near Pretoria, 
the capital city of the Republic of South Africa. 
HIV-infected children aged 4–24 months who had been previously admitted to the pediatric wards 
of the hospital with pneumonia or diarrhea were enrolled into the study, on discharge from the wards 
or from the pediatric outpatient department from November 2005 to November 2006. 
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Children who were on ART, or had received micronutrient supplementation (in the previous two 
months) or children with a chronic illness were not eligible for enrolment. At the time when the study 
was conducted, micronutrient supplementation was not standard care in HIV-infected children at the 
hospital. There were also concerns about zinc supplementation to HIV-infected children at the time. 
The Medunsa Research Ethics and Publications Committee approved the study; the permission of 
the hospital authorities was obtained, and the parents or guardians provided signed informed consent. 
The children were referred to the ART clinic when necessary as per standard hospital procedure 
(immunological and clinical staging was used) and taken off the study when ARV therapy 
commenced. At the time of conducting the study, only children with CD4 percentage <15% or those 
with clinical stage 3 or 4 were eligible to receive ART. 
In a double-blind, placebo controlled study; children were assigned to one of two intervention 
groups by computer randomization (1:1). The manufacturer prepared packs of tablets corresponding to 
the subject’s number according to the randomization schedule. The investigators, field workers and 
participants were blinded to the treatment assignments, which were revealed after completing data 
analysis. The children had monthly appointments at the hospital for follow up weight and height 
measurements, collection of tablets, and evaluation of side-effects of micronutrients. 
At enrolment and at the third and sixth monthly hospital visits, blood samples were taken for serum 
zinc, retinol, iron and ferritin and CD4 T-lymphocyte counts. 
The tablets were prepared by the pharmaceutical company Adminicle Trading (Edenvale, South 
Africa). The multi-micronutrient supplement was a crushable tablet which contained 300 µg retinol, 
0.6 mg thiamin, 0.6 mg riboflavin, 8 mg niacin, 0.6 mg pyridoxine, 1 µg cobalamin, 70 µg folic acid, 
25 mg ascorbic acid, 5 µg 1,25-dihydrocholecalciferol, 7 mg D,L-tocopherol, 700 µg copper, 8 mg 
iron, 30 µg selenium, and 8 mg zinc at amounts approximately based on recommended dietary 
allowances for a one year old child [18]. The placebo and supplement tablets were identical in 
appearance and taste. The caregiver crushed the tablet using a pill crusher and mixed it with a small 
portion of the breakfast cereal which was fed to the child before the rest of the meal. 
2.1. HIV Tests 
In children older than 15 months HIV-1 and HIV-2 serostatus was ascertained with ELISA tests [19]; 
in younger children a PCR was performed additionally. The CD4 T-lymphocyte counts were  
measured by means of a Coulter flow cytometer (Coulter Epics XL-MCL, Beckman Coulter, 
Johannesburg, South Africa) to stage the HIV infection. 
2.2. Anthropometry 
The subject’s age was calculated from the date of birth. The weight was measured with the child 
wearing only light clothing to the nearest 0.1 kg, using one digital scale, which was calibrated using a 
standard weight of 10 kg. The length was measured on a baby board in the recumbent position to  
0.1 cm. Z scores for weight-for-age (WAZ), height-for-age (HAZ), and weight-for-height (WHZ) were 
calculated based on the World Health Organization standard values by means of the freely available 
Epi-Info Version 3.5.4 software. 
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2.3. Blood Sampling and Analysis 
Blood samples (8 mL) were collected after an overnight fast by venipuncture (site cleaned with 
trace element free alcohol) from the cubital fossa or external jugular vein. Samples were collected in 
eight separate trace element free tubes, with a removable non-rubber lid protected from light, sent to 
the laboratory immediately after collection, and stored at −20 °C after centrifugation, until analysis. 
They were evaluated for hemolysis. 
Serum zinc samples were measured by atomic absorption spectrometry (Perkin Elmer ICP/5500, 
Perkin Elmer Life and Analytical Sciences Inc., Waltham, MA, USA), serum retinol measurements by 
the fluorometric method [20], serum iron levels were measured by using rate spectrophotometry 
(SYNCHRON CX Systems IRON/TIBC Calibrator Kit, Beckman Instruments, Johannesburg, South 
Africa) and serum ferritin levels using commercial enzyme-linked immunoassay kits (Access Ferritin 
assay, Access Immunoassay Systems, Beckman Coulter, Johannesburg, South Africa). Quality control 
was performed by repeat analysis of standard reference material for low, normal and high values. The 
intra-assay and inter-assay coefficients of variation for serum zinc, retinol and ferritin were all less 
than 5%. 
2.4. Morbidity 
The children were visited at home twice a week by a field worker who assessed whether the child 
was suffering from diarrhea or symptoms of acute respiratory tract infection, and when the symptoms 
resolved. Compliance was evaluated by pill count. The children were referred to hospital when 
necessary. Diarrhea was present on any day when the child passed three or more loose stools  
in that day [21]. Acute respiratory symptoms were defined as the history of cough and fever. 
2.5. Sample Size 
A sample size calculation of 72 per group was calculated to be sufficient to detect a 30% difference 
in respiratory symptoms between placebo and supplement. The calculations were made considering a 
5% level of significance and 80% power and based on information (standard deviation) from a study 
conducted on young Peruvian children [22]. In relation to improvement in weight-for-height and 
height-for-age Z-scores, the required sample sizes were 64 and 71, respectively. This was also based 
on the hypothesis that the supplement would result in a 30% improvement in these anthropometric 
indices when compared with placebo, at 5% significance and 80% power. The information was based 
on a study comparing the nutritional status of HIV-infected and HIV-uninfected children, which was 
conducted at the same hospital [2]. It was thus decided to enrol at least 90 per group to account for a 
possible 25% dropout rate; enrolling a total of 200 subjects was thus thought to be adequate. 
3. Statistical Analysis 
Data entry and analyses were performed on SPSS Statistics for Windows, version 18.0 [23]. 
Statistical analyses were two-tailed where appropriate and statistical significance was set at 5%. Data 
were assessed for normality and normalized by log transformation for serum ferritin. 
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The differences in anthropometric indices, and male to female ratios between the children who 
completed the study and those who dropped out were assessed by analysis of variance (ANOVA) and 
chi-square, respectively. 
Anthropometric indices, micronutrient concentrations and immunological parameters were studied by 
means of ANOVA for repeated measures with treatment group and gender as between subjects’ factors. 
Changes in these measurements over 3 months and 6 months and differences between the two 
treatment groups were assessed using ANOVA by treatment group with age as a co-variant. The 
number of diarrheal and pneumonia episodes per month in the two treatment groups were compared 
using ANOVA by treatment group, age and gender. 
4. Results 
The number of children who were assessed for eligibility was 837; 636 were excluded and among 
these, 524 were not eligible. Out of the 524 who were not eligible, 486 of them were not HIV-infected, 
17 were not in the eligible age group and 21 were on ART (see Figure 1). A total of 201 children aged 
4–24 months were enrolled; 121 completed the study. Among the 80 children who dropped out (40%), 
43 died, 11 received treatment with ART, 13 relocated to another area and another 13 dropped out for 
other reasons. Among the children who died, 80% died within the first month of follow up. The 
number of children who died and those who relocated was higher in the supplement group. The 
difference in mortality between the supplement and placebo group (27 versus 16, respectively) was not 
statistically significant (p = 0.12). On the other hand, the number of children who received ART was 
higher in the placebo group; this too was not statistically significant (p = 0.13). 
The anthropometric indices and CD4 T-lymphocytes (at enrolment) of the study children who 
received the supplements and those who were given a placebo are compared in Table 1. The children 
who were given the supplements were 1.5 months older than those on placebos. In relation to the 
children who did not complete the six months follow up; there were no differences in the ages and the 
ratio of males to females compared with those who were followed up for the full six month period. The 
children who dropped out were significantly more stunted and underweight and marginally more 
wasted than those who completed the study, in both treatment groups. The percentages of CD4  
T-lymphocytes of the children who dropped out were lower than those who completed the study; this 
however, was not statistically significant. Pill packets were returned at 294 of 372 scheduled visits 
(79%) for the placebo group by those who completed the study. Among those in the supplement group 
(who completed the study) pills were returned at 286 of 354 scheduled visits (81%); the difference was 
not statistically significant. The proportion of children with 2–5 pills was 8% and 9% in the placebo 
and supplement groups, respectively. There were no children with more than 5 pills in the pill packet. 
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Figure 1. Assessment for eligibility, enrolment and losses to follow-up by treatment group. 
Analysis for the number of episodes of respiratory symptoms and of diarrhea was only 
conducted among children who were followed up for three or more months. The number of 
episodes was then divided by the number of months of follow-up. Analysis for changes in 
anthropometric indices, serum micronutrient concentrations and CD4 lymphocyte counts 
was only performed in children who had completed the study. 
 
Table 1. Anthropometric indices and CD4 T-lymphocytes of study children at enrolment. 
Indices Placebo Supplement All Study Children 
n 97 104 201 
Male/Female 43/54 51/53 94/107 
Age (months) 12.02 ± 6.49 13.45 ± 6.66 12.76 ± 6.60 
Weight (kg) 7.10 ± 1.83 7.20 ± 1.99 7.15 ± 1.92 
Height (cm) 68.87 ± 7.86 70.61 ± 7.43 69.77 ± 7.67 
WAZ −2.12 ± 1.61 −2.42 ± 1.46 −2.28 ± 1.54 
HAZ −1.82 ± 1.79 −1.75 ± 1.66 −1.78 ± 1.72 
WHZ −1.23 ± 1.29 −1.71 ± 1.31 −1.48 ± 1.32 
CD4 percent (n) 24.71 ± 12.67 (63) 23.89 ± 13.15 (57) 24.32 ± 12.85 (120) 
Values presented as mean ± SD. 
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The immunological status of the children who completed the six months follow up was poor as 
denoted by the CD4 T-lymphocyte percentage (Table 2). At enrolment about 50% of the children in 
the placebo and supplement groups had CD4 T-lymphocyte proportions below 25%. The CD4  
T-lymphocyte percentage did not improve within both treatment groups and there was no significant 
difference between the two groups. 
Table 2. Immunological status of children during intervention period #. 
 Placebo Supplement 
Follow Up n CD4 Percentage n CD4 Percentage 
Enrolment 63 24.7 (21.6 to 27.9) 57 23.9 (20.5 to 27.3) 
3 mo 48 27.1 (23.3 to 30.9) 41 23.9 (19.8 to 27.9)  
6 mo 42 28.0 (24.2 to 31.7) 35 25.3 (20.8 to 29.9) 
Δ3mo 48 −0.83 (−2.68 to 1.02) 41 −2.06 (−4.33 to 0.01) 
Δ 6 mo 42 −1.44 (−3.71 to 0.83) 35 −0.64 (−3.39 to 2.11) 
Values presented as mean (95% CI); # There were no significant differences between the two treatment 
groups in both absolute values and changes over 3 and 6 months. 
The concentrations of serum zinc, retinol and ferritin over the 6 month period are presented in  
Table 3. There were no significant differences in the zinc and retinol concentrations between the two 
treatment groups at enrolment. The zinc concentrations improved significantly (by 14%) over the  
6 month period within the supplement group, but not significantly within the placebo group. 
Nonetheless, there was no significant difference in the absolute change of serum zinc concentrations 
between the two treatment groups. The retinol concentrations did not differ significantly through the  
6 month period within each treatment group and between the two treatment groups. The log ferritin 
increased by 0.1 in the supplement group. On the other hand, among children on placebos the log 
ferritin value deteriorated significantly. 
The anthropometric indices derived from the weights and heights (WAZ, HAZ and WHZ) of the 
children who completed the six month follow up period are shown in Table 4. The weights of the 
children increased significantly, by 1.35 kg in the placebo group and by 1.66 kg in the supplement 
group. Through the period of follow-up, there was a significant increase in height of 5.95 cm in the 
placebo group and 5.98 cm in the supplement group. Neither weight gain nor height increase was 
different between the two groups. There were no significant differences at enrolment between the two 
treatment groups in WAZ, HAZ and WHZ (Table 4), but the absolute low values of the Z-scores 
indicate that a large proportion of the children should be classified as wasted and stunted. WHZ as 
indicator for wasting and HAZ as indicator for stunting are graphically presented in Figure 2. Over the 
6 month intervention there was a significant improvement in WAZ and WHZ values among the 
children in the supplement group but not in the placebo group. This improvement in WAZ and WHZ 
was shown to be independent of the children’s ages on ANOVA. The change in HAZ did not differ 
between the groups. 
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Table 3. Micronutrient status of the children during intervention period. 
 Supplement Placebo 
Follow Up Zinc (µmol/L) Retinol (µmol/L)  Log Ferritin (log[µg/L]) Zinc (µmol/L) Retinol (µmol/L) Log Ferritin (log[µg/L]) 
Enrolment 9.6 (8.8 to 10.5) (n = 75) 0.81 (0.70 to 0.95) (n = 62) 1.70 (1.58 to 1.81) (n = 75) 9.0 (8.3 to 9.7) (n = 78) 0.87 (0.75 to 0.99) (n = 53) 1.62 (1.52 to 1.73) (n = 78) 
3 mo 9.8 (8.8 to 10.8) (n = 58) 0.78 (0.70 to 0.88) (n = 42) 1.54 (1.43 to 1.66) (n = 59) 10.4 (9.7 to 11.2) (n = 56) 0.84 (0.73 to 0.96) (n = 36) 1.66 (1.57 to 1.75) (n = 55) 
6 mo 10.4 (9.5 to 11.3) (n = 53) 0.72 (0.65 to 0.79) (n = 34) 1.54 (1.40 to 1.68) (n = 52) 10.5 (9.6 to 11.4) (n = 51) 0.85 (0.70 to 1.0) (n = 32) 1.61 (1.51 to 1.71) (n = 49) 
Δ3mo −0.27 (−1.28 to 0.80) (n = 58) −0.03 (−0.17 to 0.01) (n = 42) −0.11 (−0.21 to −0.01) (n = 59) 1.17 (0.16 to 2.10) (n = 56) 0.01 (−0.16 to 0.15) (n = 36) 0.12 (0.03 to 0.21) (n = 55) 
Δ 6 mo 0.41 (−0.67 to 1.50) (n = 53) −0.05 (−0.21 to 0.11) (n = 34) −0.06 (−0.17 to 0.05) (n = 52) 1.26 (0.14 to 2.39) (n = 51) −0.01 (−0.24 to 0.22) (n = 32) 0.10 (−0.01 to 0.21) (n = 49) 
Values presented as mean (95% CI). 
Table 4. Anthropometric indices of the children during intervention period. 
  Placebo Supplement 
Follow Up  n Age (mo) WAZ HAZ WHZ n Age (mo) WAZ HAZ WHZ 
Enrolment  97
12.0  
(10.7 to 13.3) 
−2.12  
(−2.44 to −1.80) 
−1.82  
(−2.18 to −1.46)
−1.23  
(−1.49 to −0.97) 104 
13.5  
(12.2 to 14.7)
−2.42  
(−2.70 to −2.14) 
−1.75  
(−2.07 to −1.43)
−1.71  
(−1.96 to −1.46) 
1 mo  77
13.5  
(12.0 to 15.1) 
−1.96  
(−2.32 to −1.61) 
−1.69  
(−2.08 to −1.30)
−1.11  
(−1.39 to −0.83) 73 
15.0  
(13.5 to 16.5)
−2.08  
(−2.43 to − 1.73)
−1.50  
(−1.83 to −1.17)
−1.48  
(−1.77 to −1.19) 
2 mo  72
14.5  
(12.9 to 16.1) 
−2.03  
(−2.41 to −1.65) 
−1.69  
(−2.09 to −1.29)
−1.21  
(−1.50 to −0.92) 70 
16.3  
(14.7 to 17.8)
−2.01  
(−2.38 to −1.64) 
−1.53  
(−1.88 to −1.18)
−1.36  
(−1.66 to −1.07) 
3 mo  66
15.6  
(14.2 to 17.0) 
−1.90  
(−2.30 to −1.50) 
−1.63  
(−2.04 to −1.22)
−1.08  
(−1.37 to −0.79) 66 
17.1  
(15.5 to 18.7)
−1.96  
(−2.34 to −1.58) 
−1.51  
(−1.87 to −1.15)
−1.31  
(−1.64 to −0.98) 
4 mo  62
16.6  
(14.8 to 18.4) 
−1.80  
(−2.20 to −1.40) 
−1.46  
(−1.86 to −1.06)
−1.10  
(−1.41 to −0.79) 62 
18.1  
(16.4 to 19.7)
−1.82  
(−2.19 to −1.45) 
−1.37  
(−1.74 to 1.00)
−1.24  
(−1.53 to −0.95) 
5 mo  62
17.6  
(15.8 to 19.4) 
−1.84  
(−2.25 to −1.43) 
−1.45  
(−1.88 to −1.02)
−1.17  
(−1.48 to −0.86) 62 
19.0  
(17.3 to 20.6)
−1.78  
(−2.15 to −1.41) 
−1.35  
(−1.73 to −0.97)
−1.20  
(−1.50 to −0.90) 
6 mo  62
18.5  
(16.7 to 20.3) 
−1.85  
(−2.27 to −1.43) 
−1.26  
(−1.67 to −0.85)
−1.27  
(−1.56 to −0.98) 59 
20.0  
(18.3 to 21.7)
−1.58  
(−1.97 to –1.19) 
−1.14  
(−1.55 to −0.73)
−1.08  
(−1.40 to −0.76) 
Δ3 mo  66 3.5 −0.11  
(−0.28 to 0.06) 
−0.20  
(−0.34 to −0.06) $
0.08  
(−0.15 to 0.31) 66 3.2 
0.08  
(−0.12 to 0.28) # 
−0.16  
(−0.36 to 0.04)
0.22  
(0.01 to 0.44) $ 
Δ 6 mo  62 5.6 −0.19  
(−0.46 to 0.08) 
−0.03  
(−0.25 to 0.19) 
−0.04  
(−0.39 to 0.31) 59 5.8 
0.39  
(0.12 to 0.66) $,# 
0.09  
(−0.15 to 0.33)
0.40  
(0.09 to 0.71) $,# 
Values presented as mean (95% CI) # Significantly different from placebo group (p < 0.05); $ Significantly different from zero (p < 0.05). 
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Figure 2. Change in anthropometrics Z-scores over the six month follow-up period among 
children who completed the study. 
 
The episodes of respiratory symptoms and of diarrhea were analyzed for children who had been 
followed up for 3 or more months. The number of episodes was then divided by the number of months 
of follow-up; these are presented in Table 5. The ages of these children were similar in the two 
treatment groups. The children who received the supplements had fewer episodes of diarrhea per 
month (0.25 (0.17–0.33)) (mean 95% CI) compared to those who were given placebos  
(0.36 (0.26–0.46)) (p = 0.09) and substantially lower number of episodes of respiratory symptoms: 
0.66 (0.52–0.80) versus 1.01 (0.83–1.19) (p < 0.05); the latter difference was independent of the 
children’s ages on ANOVA. 
Table 5. Diarrhea and respiratory symptom episodes per month of follow up. 
Treatment 
Group 
n 
Age at Enrolment 
(months) 
Number of Diarrheal 
Episodes per Month 
Number of Episodes of 
Respiratory Symptoms 
per Month 
Placebo 53 12.0 (10.3–13.7) 0.36 (0.26–0.46) 1.01 (0.83–1.19) 
Supplement 52 13.7 (12.1–15.3) 0.25 (0.17–0.33) * 0.66 (0.52–0.80) # 
Values presented as mean (95% CI) * Marginally significantly different from placebo group (p = 0.09);  
# Significantly different from placebo group (p < 0.05). 
5. Discussion 
The objective of the study was to assess the impact of six month multi-micronutrient 
supplementation on growth performance and number of episodes of diarrhea and respiratory symptoms 
of HIV-infected children. 
There was a high proportion of study children who did not complete the six month follow up period 
(40%); this can be considered as a limitation in this study. Among these children who did not complete 
the follow up period, the mortality was high, at 54% (21% of all enrolled children). The number of 
children who died was higher in the group that received the supplements (not statistically significant), 
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and 80% of these children died within the first month of follow up in both treatment groups. However, 
the fact that most of the deaths occurred within the first month does not exclude the possibility that the 
micronutrients might have had a role in this. It is should also be noted that the children who received 
the supplements were also more wasted than those who were on the placebo; this finding was also not 
statistically significant. A pooled analysis of studies conducted in West, East and South Africa 
estimated that by two years of age, 53% of HIV-infected children would have died [24]. A survey that 
reviewed the mortality in a number of South African hospitals noted that approximately 48% of the 
deaths of children admitted to these hospitals were related to HIV infection [25]. Only 11 (14% of the 
total number of dropouts) children were commenced on ART in the current study. The ART program 
was only rolled out in South Africa in 2004. The relatively low proportion of children who received ART 
in the study may be related to the fact that the rollout of the ART program was still at an early stage. 
Children who dropped out were significantly more stunted and more wasted at enrolment than those 
who completed the study in both groups but the difference in wasting approached significance only 
among children who received the supplement. This chance finding occurred in spite of careful 
randomization procedures. Poor growth has been linked with increased mortality in HIV-infected 
children. This is supported by a study that indicated that wasting and stunting in HIV-infected children 
are associated with increased mortality [5]. The immunological status (as measured by the percentage 
of CD4 T-lymphocytes) of the children who dropped out in the current study was significantly worse 
than that of those who completed the study. This finding is in line with a meta-analysis of 10 studies 
that suggested that CD4 measurements are the most important indicator of mortality in HIV-infected 
children not receiving ART [26]. 
Supplementation with micronutrients over a period of six months did not have an effect on the 
immunological status as measured by the CD4 T-lymphocytes in the current study. This is in keeping 
with a study in which zinc supplementation in HIV-infected young South African children had no 
effect on the percentage of CD4 lymphocytes when compared with a placebo [27]. In pregnant  
HIV-infected Tanzanian women, however, multivitamin supplementation significantly improved the 
women’s CD4 counts, compared with women who received a placebo [28]. 
The concentrations of serum zinc improved significantly over the study period among children who 
received the multi-micronutrient supplement. However, the absolute change in serum zinc and retinol 
concentrations was not significantly different between the two treatment groups. On the other hand 
was a significant difference in the change in log ferritin (it was higher in the supplement group). 
Unfortunately, blood samples for acute phase reactants (e.g., C-reactive protein) were not taken; this 
might have hampered the assessment of the difference in micronutrient concentrations. 
In the current study, the improvement in WAZ and WHZ over the six month period was 
significantly greater among children who were given the supplements. However, the supplements had 
no effect on stunting. It is important to note that the children who received the supplements were  
1.5 months older than those who were on the placebo. Nonetheless, the improvement in WAZ and 
WHZ was independent of age. In Peru (an area with low HIV prevalence), no improvement was noted 
in WAZ and HAZ in children who were given multi-micronutrients [22]. Supplementation with 
multiple micronutrients combined with vitamin A in stunted South African children (6–24 months of 
age) significantly improved height, compared with vitamin A alone or vitamin A plus zinc [29]. It has 
been suggested that micronutrient supplements are more effective in children who have poor 
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anthropometric indices. The children in the current study were more wasted and stunted than the 
children in the above noted studies. The multi-micronutrients were given for six months in both the 
current and the Peruvian studies. However, in the study with stunted South African children, the 
supplements were given for 18 months. It is thus conceivable that the six month period of 
supplementation in the current study might have been too short. 
In the current study, children who received the micronutrient supplement had significantly fewer 
episodes of respiratory symptoms and fewer episodes of diarrhea than those who were on the placebo; 
the difference in diarrheal episodes did not reach statistical significance. In young South African children 
(6–24 months of age) who were born to HIV-infected mothers, receipt of a multi-micronutrient 
supplement (that included vitamin A) did not reduce the prevalence of diarrhea or respiratory 
symptoms when compared with children who were given vitamin A only irrespective of HIV  
status [30]. However, multi-micronutrient supplementation reduced the incidence of diarrhea in rural 
South African children compared with those who received vitamin A only; the reduction was only 
noted in stunted HIV-uninfected children [31]. Similarly, zinc supplements significantly reduced 
episodes of diarrhea in HIV-infected South African children; episodes of pneumonia, however, were 
marginally reduced [26]. A meta-analysis of 17 studies (from areas with low HIV prevalence) concluded 
that zinc supplementation significantly reduced the risk of diarrhea and respiratory illnesses [32]. 
6. Conclusions 
The improvement in growth performance (in weight but not height) and reduction in morbidity that 
was observed in this study suggests that micronutrient supplements are useful as adjunct therapy in 
HIV-infected children. While there was no effect on CD4 lymphocytes, there were no deleterious 
effects. At the time of conducting the study, ART was not widely available at the local hospital, but 
has since become available to an increasing number of children in sub-Saharan African countries. 
However, because ART is given to children with advanced HIV disease, micronutrient supplementation 
may be useful in those children who are as yet not eligible for ART. The effect of micronutrient 
supplementation in children who are on ART should also be investigated. 
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